Promising drug combo targets rare spine tumor

This early-phase study tested the safety of combining the drug nilotinib with standard radiation therapy for people with high-risk chordoma, a rare bone tumor. The goal was to find the highest safe dose of nilotinib that could be given alongside radiation without causing severe side effects. Twenty-three participants were enrolled to help determine the best dose for future studies.